Erectile Dysfunction in Diabetes Mellitus

被引:299
作者
Malavige, Lasantha S. [1 ,2 ,3 ]
Levy, Jonathan C. [1 ,2 ]
机构
[1] Univ Oxford, Nuffield Dept Clin Med, Oxford OX3 7LJ, England
[2] Oxford Radcliffe Trust, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England
[3] Univ Sri Jayewardenepura, Dept Med, Nugegoda, Sri Lanka
关键词
Erectile Dysfunction; Diabetes; Hypogonadism; Testosterone; PDE5; Inhibitors; Pathophysilogy; QUALITY-OF-LIFE; RISK-FACTORS; PEYRONIES-DISEASE; INSULIN-RESISTANCE; ENDOTHELIAL DYSFUNCTION; INTERNATIONAL INDEX; SEXUAL DYSFUNCTION; METABOLIC SYNDROME; CORPORA CAVERNOSA; GLYCEMIC CONTROL;
D O I
10.1111/j.1743-6109.2008.01168.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is reaching pandemic levels and young-onset type 2 diabetes is becoming increasingly common. Erectile dysfunction (ED) is a common and distressing complication of diabetes. The pathophysiology and management of diabetic ED is significantly different to nondiabetic ED. To provide an update on the epidemiology, risk factors, pathophysiology, and management of diabetic ED. Literature for this review was obtained from Medline and Embase searches and from relevant text books. A comprehensive review on epidemiology, risk factors, pathophysiolgy, and management of diabetic ED. Large differences in the reported prevalence of ED from 35% to 90% among diabetic men could be due to differences in methodology and population characteristics. Advancing age, duration of diabetes, poor glycaemic control, hypertension, hyperlipidemia, sedentary lifestyle, smoking, and presence of other diabetic complications have been shown to be associated with diabetic ED in cross-sectional studies. Diabetic ED is multifactorial in aetiology and is more severe and more resistant to treatment compared with nondiabetic ED. Optimized glycaemic control, management of associated comorbidities and lifestyle modifications are essential in all patients. Psychosexual and relationship counseling would be beneficial for men with such coexisting problems. Hypogonadism, commonly found in diabetes, may need identification and treatment. Maximal doses of phosphodiesterase type 5 (PDE5) inhibitors are often needed. Transurethral prostaglandins, intracavenorsal injections, vacuum devices, and penile implants are the available therapeutic options for nonresponders to PDE5 inhibitors and for whom PDE5 inhibitors are contraindicated. Premature ejaculation and reduced libido are conditions commonly associated with diabetic ED and should be identified and treated. Aetiology of diabetic ED is multifactorial although the relative significance of these factors are not clear. A holistic approach is needed in the management of diabetic ED. Malavige LS, and Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009;6:1232-1247.
引用
收藏
页码:1232 / 1247
页数:16
相关论文
共 134 条
  • [51] Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both
    Giuliano, FA
    Leriche, A
    Jaudinot, EO
    de Gendre, AS
    [J]. UROLOGY, 2004, 64 (06) : 1196 - 1201
  • [52] Oral sildenafil in the treatment of erectile dysfunction
    Goldstein, I
    Lue, TF
    Padma-Nathan, H
    Rosen, RC
    Steers, WD
    Wicker, PA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) : 1397 - 1404
  • [53] Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes - A multicenter double-blind placebo-controlled fixed-dose study
    Goldstein, I
    Young, JM
    Fischer, J
    Bangerter, K
    Segerson, T
    Taylor, T
    [J]. DIABETES CARE, 2003, 26 (03) : 777 - 783
  • [54] Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil
    Gruenwald, Ilan
    Shenfeld, Ofer
    Chen, Juza
    Raviv, Gil
    Richter, Santiago
    Cohen, Ayala
    Vardi, Yoram
    [J]. EUROPEAN UROLOGY, 2006, 50 (01) : 134 - 140
  • [55] Guay AT, 2001, J ANDROL, V22, P793
  • [56] Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome
    Hamdy, O
    Ledbury, S
    Mullooly, C
    Jarema, C
    Porter, S
    Ovalle, K
    Moussa, A
    Caselli, A
    Caballero, AE
    Economides, PA
    Veves, A
    Horton, ES
    [J]. DIABETES CARE, 2003, 26 (07) : 2119 - 2125
  • [57] Diagnostic steps in the evaluation of patients with erectile dysfunction
    Hatzichristou, D
    Hatzimouratidis, K
    Bekas, M
    Apostolidis, A
    Tzortzis, V
    Yannakoyorgos, K
    [J]. JOURNAL OF UROLOGY, 2002, 168 (02) : 615 - 620
  • [58] Treatment strategy for "non-responders" to tadalafil and vardenafil: A real-life study
    Hatzimouratidis, Konstantinos
    Moysidis, Kyriakos
    Bekos, Athanasios
    Tsimtsiou, Zoi
    Ioannidis, Evangelos
    Hatzichristou, Dimitrios
    [J]. EUROPEAN UROLOGY, 2006, 50 (01) : 126 - 133
  • [59] Neuropathy is a major contributing factor to diabetic erectile dysfunction
    Hecht, MJ
    Neundörfer, B
    Kiesewetter, F
    Hilz, MJ
    [J]. NEUROLOGICAL RESEARCH, 2001, 23 (06) : 651 - 654
  • [60] Erectile dysfunction severity might be associated with poor cardiovascular prognosis in diabetic men
    Heruti, Rafi J.
    Uri, Inbal
    Arbel, Yaron
    Swartzon, Michael
    Galor, Shay
    Justo, Dan
    [J]. JOURNAL OF SEXUAL MEDICINE, 2007, 4 (02) : 465 - 471